Supplementary Material for “Sensitivity Analyses Comparing Time-to-Event Outcomes Only Existing in a Subset Selected Postrandomization and Relaxing Monotonicity”

Bryan E. Shepherd, Peter B. Gilbert, and Charles T. Dupont
Figure 1: Sensitivity analysis of $SCE(2)$ for the non-white cohort of VaxGen’s Phase III trial, where the principal stratum of interest is those who would have been infected regardless of treatment assignment within 3 years of randomization.
Figure 2: Sensitivity analysis of $SCE(2)$ for the non-white cohort of VaxGen’s Phase III trial, where the principal stratum of interest is those who would have been infected regardless of treatment assignment within 2 years of randomization.
Figure 3: Sensitivity analysis of $SCE(4)$ for the non-white cohort of VaxGen’s Phase III trial, where the principal stratum of interest is those who would have been infected regardless of treatment assignment within 3 years of randomization, and the outcome is time from randomization until initiation of antiretroviral therapy.